Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant

Launched by RIGSHOSPITALET, DENMARK · Nov 15, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how diseases like leukemia and lymphoma, as well as treatments like stem cell transplants, affect muscle strength and function in patients. Researchers want to understand if muscle problems can give important clues about a patient’s health and treatment decisions. The trial is currently recruiting patients aged 65 to 74 who have been diagnosed with specific blood cancers and are being considered for different types of stem cell transplants.

To be eligible, patients must have certain types of blood cancers and be referred to a stem cell transplant at Rigshospitalet in Denmark. Participants will be asked to undergo tests to check their muscle function and will be monitored throughout the trial. This research aims to help doctors understand how muscle health impacts recovery and treatment outcomes, which could lead to better care for patients with these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with acute myelogenous leukaemia (AML), acute lymphatic leukaemia (ALL), chronic myelomonocytic leukaemia (CMML), myelodysplastic syndrome (MDS), chronic lymphatic leukaemia (CLL), malignant lymphomas or multiple myeloma (MM) referred to myeloablative HSCT, myeloablative RTC-HSCT or non-myeloablative HSCT at the Department of Haematology, Rigshospitalet, Blegdamsvej.
• Exclusion Criteria:
• • age \<18; pregnancy; physical or mental disabilities precluding test of muscle function; inability to read and understand Danish